First regulatory approval for the first-of-its-kind, fully-integrated PFA system with a simple and reproducible workflow Integrated with the world’s leading CARTO™ 3D cardiac mapping system for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation (AFib)…
Tag: Biosense Webster
Biosense Webster Study Links Lower Risk of Heart Failure in Atrial Fibrillation Patients Treated with Catheter Ablation Compared to Antiarrhythmic Drugs
Irvine, CA October 5, 2023 – Biosense Webster, Inc. the global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,1 announced today new data from a Biosense Webster funded study which sought to compare the risk of heart failure incidence among atrial fibrillation (AFib) patients treated with catheter ablation versus antiarrhythmic drugs […]
Biosense Webster Receives FDA Approval for Multiple Atrial Fibrillation Ablation Products to be Used in a Workflow Without Fluoroscopy
IRVINE, Calif., Aug. 4, 2023 /PRNewswire/ — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i today announced that several products in its market-leading cardiac ablation portfolio have received approval for a zero fluoroscopy workflow from the U.S. Food and Drug Administration (FDA). The products that can be used in […]
New Data Published on Biosense Webster QDOT MICRO™ Catheter – the Latest Advancement in Focal RF Ablation for Treating AFib
Showed high clinical success with 86% freedom from symptomatic recurrence1 Temperature control allows for the safe use of higher RF power in short bursts, enhancing efficacy and efficiency without compromising safety1 IRVINE, Calif., May 15, 2023 /PRNewswire/ — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i announced that data from […]
Biosense Webster’s First Dual Energy Catheter to Treat Atrial Fibrillation Begins Evaluation in SmartfIRE Clinical Trial
Study will evaluate THERMOCOOL SMARTTOUCH™ SF Dual Energy Catheter’s potential to enable safer and simpler procedures with the ability to deliver both radiofrequency and pulsed field ablation Irvine, CA – March 7, 2023 – Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i announced today the first cases with […]
First Look at Data on Biosense Webster’s Investigational Pulsed Field Ablation Platform Presented at AF Symposium 2023
Late breaking analysis of one-year outcomes from the inspIRE clinical study demonstrated early success at the prespecified interim analysis Irvine, CA – February 3, 2023 – Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i announced that positive results from the inspIRE company-sponsored clinical trial were presented as a […]
Late Breaking Data on Pulmonary Vein Isolation with HELIOSTAR™ Balloon Ablation Catheter Presented at AF Symposium 2023
Presentation details results from Biosense Webster’s global, multicenter STELLAR study Irvine, CA – February 3, 2023 – Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi, announced that positive results from the company-sponsored STELLAR study were presented as a late breaker, titled “Pulmonary Vein Isolation of Paroxysmal Atrial […]
Biosense Webster Launches HELIOSTAR™ in Europe, the First Radiofrequency Balloon Ablation Catheter, Enabling Physicians to Perform More Efficient Cardiac Ablations
The HELIOSTAR™ Balloon Ablation Catheter’s unique one-shot balloon technology enables pulmonary vein isolation in 12 seconds, with customized energy delivery and one integrated 3D mapping solution1 IRVINE, Calif., Oct. 13, 2022 /PRNewswire/ — Biosense Webster, Inc., part of Johnson & Johnson MedTech†, today announced the European launch of the HELIOSTAR™ Balloon Ablation Catheter – the first radiofrequency […]
Biosense Webster Launches the OCTARAY™ Mapping Catheter with TRUEref™ Technology
The OCTARAY™ Mapping Catheter with TRUEref™ Technology provides physicians with the precise information needed for catheter ablation procedures that treat cardiac arrhythmias1,2† IRVINE, Calif., Sept. 6, 2022 /PRNewswire/ — Biosense Webster, Inc., part of Johnson & Johnson MedTech‡, today announced the release of the OCTARAY™ Mapping Catheter with TRUEref™ Technology powered by the CARTO™ 3 Version 7 System. […]
Biosense Webster Receives FDA Approval for THERMOCOOL SMARTTOUCH® SF Ablation Catheter for the Treatment of Persistent Atrial Fibrillation
The CARTO® 3 System and THERMOCOOL SMARTTOUCH® SF Catheter allow for a patient-tailored ablation approach, resulting in high long-term effectiveness in persistent atrial fibrillation patients* IRVINE, Calif., Oct. 6, 2020 /PRNewswire/ — Johnson & Johnson Medical Devices Companies** today announced the United States Food and Drug Administration (FDA) approval of Biosense Webster, Inc.’s THERMOCOOL SMARTTOUCH® SF Ablation Catheter for the […]
Recent
$5 Million Gift from Lorraine and Bill Dodero Creates One-of-a-Kind Limb Preservation Center at University Hospitals Harrington Heart & Vascular Institute
Florida’s Space Coast Expands Access To Advanced Cardiology Screening with Arrival of SpotLight™ Scanner
Pepin Heart Institute at AdventHealth Tampa expands with fourth electrophysiology lab
Popular
- No commented posts yet